Annual Revenue,rose 8.92%, in the last year to ₹3,895.14 Cr. Its sector's average revenue growth for the last fiscal year was 10.77%.
Annual Net Profit,rose 56.57% in the last year to ₹930.24 Cr. Its sector's average net profit growth for the last fiscal year was 38.71%.
Return on Equity(ROE),for the last financial year was 47.67%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
View more
LONG-TERM PRICE ANALYSIS
Stock return5Y CAGR : 8.45%
Net profit growth 5Y CAGR : 5.78%
Glaxosmithkline Pharmaceuticals Ltd Top mutual funds holding
Glaxosmithkline Pharmaceuticals Limited is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its RD approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.
Grow your wealth with more research recommendations